Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study.
Funakoshi Y, Takigawa K, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Otsuji R, Sako A, Yoshitake T, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Yoshimoto K.
Funakoshi Y, et al. Among authors: otsuji r.
World Neurosurg. 2022 Mar;159:e479-e487. doi: 10.1016/j.wneu.2021.12.075. Epub 2021 Dec 25.
World Neurosurg. 2022.
PMID: 34958993